Herbal Formula Improves Brain Injury Recovery by Modulating Ghrelin Pathway
Background
Traumatic Brain Injury (TBI) is a devastating neurological condition with limited effective treatments, often leading to long-term neurological dysfunction and chronic inflammation. The complex pathophysiology of TBI involves immediate mechanical damage followed by secondary injury mechanisms, including oxidative stress and neuroinflammation, which exacerbate neuronal death. Current therapeutic strategies often fall short in comprehensively addressing these multifaceted challenges, highlighting an urgent need for novel interventions. This study specifically addresses how the traditional Chinese medicine formula Danshen-Chuanxiong-Honghua (DCH) ameliorates TBI-induced neurological deficits and inflammation by modulating the Ghrelin/GHSR pathway.
Results
The study revealed that DCH treatment significantly improved neurological outcomes in TBI rats. Animals treated with DCH showed a significant reduction in neurological severity scores, with a 43% improvement observed by day 7 compared to the untreated TBI group (p<0.01). Furthermore, DCH markedly suppressed the inflammatory response in brain tissue. Levels of pro-inflammatory cytokines such as IL-6 and TNF-α were reduced by 55% and 48% respectively (p<0.001), while the anti-inflammatory cytokine IL-10 was increased by 35% (p<0.05). > The most impactful finding was that DCH treatment effectively modulated the Ghrelin/GHSR pathway, leading to a 2.5-fold increase in Ghrelin (a hormone known for neuroprotective effects) expression and a 1.8-fold upregulation of its receptor, GHSR (Growth Hormone Secretagogue Receptor), in the injured brain tissue compared to untreated TBI rats. This modulation was associated with a 30% reduction in brain edema and a 28% decrease in neuronal apoptosis, suggesting a direct link between the Ghrelin pathway activation and neuroprotection.
Why It Matters
This research highlights Danshen-Chuanxiong-Honghua (DCH) as a promising multi-target therapeutic agent for traumatic brain injury, offering both anti-inflammatory and neuroprotective benefits. The specific identification of the Ghrelin/GHSR pathway as a key mechanism of action provides a novel target for future drug development in TBI. This discovery could pave the way for new therapeutic strategies that leverage endogenous neuroprotective systems to mitigate TBI-induced damage and improve patient recovery. Future steps should involve further mechanistic studies and, if successful, progression to human clinical trials to validate these findings.